Isolation and Characterization of a Novel Bacteriophage Infecting Carbapenem-Resistant Klebsiella pneumoniae

Gao, Mingming; Wang, Can; Xin, Qiang; Liu, Huiying; Li, Puyuan; Pei, Guangqian; Zhang, Xianglilan; Mi, Zhiqiang; Huang, Yong; Tong, Yigang; Bai, Chunmei

doi:10.1007/s00284-019-01849-8

Cited by 15 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal MOI for phages varies, and the smaller the optimal MOI, the fewer phages required to lyse the same number of bacteria. The optimal MOI of vB_kpnM_17-11 was 0.001, which was similar to that reported for Klebsiella phage vB_KpnP_IME337 ( Gao et al., 2020 ), indicating that when their MOI was 0.001, the unit phage produced the most progeny and had the highest proliferation efficiency. In the industrial preparation of phages, to obtain a higher titer, researchers often culture phages based on the optimal MOI, which reduces production costs and increases profits.…”

Section: Discussionsupporting

confidence: 82%

“…Previous studies have also isolated phages that lyse CRKP, such as kpssk3 ( Shi et al., 2020 ), vB_KpnP_IME337 ( Gao et al., 2020 ), and TSK1 ( Tabassum et al., 2018 ). The biological characteristics of vB_kpnM_17-11 were not significantly different from those of these phages in terms of the one-step growth curve, temperature, and pH stability.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Bai

Zhang

Liang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Phages and phage-encoded proteins exhibit promising prospects in the treatment of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) infections. In this study, a novel Klebsiella pneumoniae phage vB_kpnM_17-11 was isolated and identified by using a CRKP host. vB_kpnM_17-11 has an icosahedral head and a retractable tail. The latent and exponential phases were 30 and 60 minutes, respectively; the burst size was 31.7 PFU/cell and the optimal MOI was 0.001. vB_kpnM_17-11 remained stable in a wide range of pH (4-8) and temperature (4-40°C). The genome of vB_kpnM_17-11 is 165,894 bp, double-stranded DNA (dsDNA), containing 275 Open Reading Frames (ORFs). It belongs to the family of Myoviridae, order Caudovirales, and has a close evolutionary relationship with Klebsiella phage PKO111. Sequence analysis showed that the 4530 bp orf022 of vB_kpnM_17-11 encodes a putative depolymerase. In vitro testing demonstrated that vB_kpnM_17-11 can decrease the number of K. pneumoniae by 105-fold. In a mouse model of infection, phage administration improved survival and reduced the number of K. pneumoniae in the abdominal cavity by 104-fold. In conclusion, vB_kpnM_17-11 showed excellent in vitro and in vivo performance against K. pneumoniae infection and constitutes a promising candidate for the development of phage therapy against CRKP.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Bai

Zhang

Liang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…To search for similar cases, we analyzed proteins containing putative depolymerase domains for 76 Klebsiella phages, presented in NCBI ( Volozhantsev et al, 2016 , 2020 ; Labudda et al, 2017 ; Solovieva et al, 2018 ; Latka et al, 2019 ; Pan et al, 2019 ; Teng et al, 2019 ; Thiry et al, 2019 ; Wu et al, 2019 ; Domingo-Calap et al, 2020a , b ; Gao et al, 2020 ; Horváth et al, 2020 ; Li et al, 2020 ; Zhang et al, 2020 ; Supplementary Figure 6 ). The depolymerase domains of our bacteriophages formed a separate cluster on the tree together with the BIS47_29 protein’s domain (GenBank: YP_009832536.1).…”

Section: Discussionmentioning

confidence: 99%

Novel Klebsiella pneumoniae K23-Specific Bacteriophages From Different Families: Similarity of Depolymerases and Their Therapeutic Potential

et al. 2021

View full text Add to dashboard Cite

Antibiotic resistance is a major public health concern in many countries worldwide. The rapid spread of multidrug-resistant (MDR) bacteria is the main driving force for the development of novel non-antibiotic antimicrobials as a therapeutic alternative. Here, we isolated and characterized three virulent bacteriophages that specifically infect and lyse MDR Klebsiella pneumoniae with K23 capsule type. The phages belonged to the Autographiviridae (vB_KpnP_Dlv622) and Myoviridae (vB_KpnM_Seu621, KpS8) families and contained highly similar receptor-binding proteins (RBPs) with polysaccharide depolymerase enzymatic activity. Based on phylogenetic analysis, a similar pattern was also noted for five other groups of depolymerases, specific against capsule types K1, K30/K69, K57, K63, and KN2. The resulting recombinant depolymerases Dep622 (phage vB_KpnP_Dlv622) and DepS8 (phage KpS8) demonstrated narrow specificity against K. pneumoniae with capsule type K23 and were able to protect Galleria mellonella larvae in a model infection with a K. pneumoniae multidrug-resistant strain. These findings expand our knowledge of the diversity of phage depolymerases and provide further evidence that bacteriophages and phage polysaccharide depolymerases represent a promising tool for antimicrobial therapy.

show abstract

“…B_VpS_BA3 and vB_VpS_CA8 phages against Vibrio parahaemolyticus were isolated from sewage collected in China [13]. The vB_KpnP_IME337 phage against carbapenem-resistant Klebsiella pneumoniae was isolated from hospital sewage in China [14]. Li et al [15] isolated 54 novel phages against the same organism from medical and domestic sewage wastewater.…”

Section: Phages As Pharmaceuticals 21 Phage Isolation and Enrichmentmentioning

confidence: 99%

Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

2021

View full text Add to dashboard Cite

Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii.

show abstract

Isolation and Characterization of a Novel Bacteriophage Infecting Carbapenem-Resistant Klebsiella pneumoniae

Cited by 15 publications

References 42 publications

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Novel Klebsiella pneumoniae K23-Specific Bacteriophages From Different Families: Similarity of Depolymerases and Their Therapeutic Potential

Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

Contact Info

Product

Resources

About